KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study.Eur J Paediatr NeurolPMID 37639777无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.Respir MedPMID 37640273无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Interim analysis of patient-reported outcome compliance and dosimetry in a phase 3 randomized clinical trial of oesophagus-sparing spinal radiotherapy.Acta OncolPMID 37647380无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials.J Am Acad DermatolPMID 37656094无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPMID 37660704无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.Ann OncolPMID 37678672无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.Lancet Gastroenterol HepatolPMID 37683686无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.J InfectPMID 37690669无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.Ann Rheum DisPMID 37696588PMC105794782023-Nov0.98未发现恶性肿瘤人群证据。待处理
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.Eur J CancerPMID 37708629无 PMCID2023-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.Adv TherPMID 37715851PMC105678912023-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.Lancet Respir MedPMID 37716365PMC108726392023-Nov0.98未发现恶性肿瘤人群证据。待处理
Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.Lung CancerPMID 37722340无 PMCID2023-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.Lancet Gastroenterol HepatolPMID 37734399PMC105675792023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.Ann Intern MedPMID 37748181无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.Diabetes Metab JPMID 37750183PMC106957082023-Nov0.98未发现恶性肿瘤人群证据。待处理
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.Curr Med Res OpinPMID 37752878无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.Curr Med Res OpinPMID 37752892无 PMCID2023-Nov0.45The study is a secondary analysis of a Phase III randomized controlled trial comparing zanubrutinib to ibrutinib in R/R CLL/SLL, with drug intervention and human oncology context. However, it is excluded because the primary endpoint is health-related quality of life (a patient-reported outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report is classified as secondary, not primary.待处理
Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.SeizurePMID 37769545无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.Lancet HIVPMID 37783219PMC108425272023-Nov0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.Lancet MicrobePMID 37783221无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.Eur J Drug Metab PharmacokinetPMID 37792130无 PMCID2023-Nov0.95The record describes a randomized Phase III trial in oncology (nsNSCLC) with a drug intervention (MYL-1402O biosimilar). However, the report focuses exclusively on population pharmacokinetic modeling and pharmacokinetic similarity. There is no mention of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or associated Kaplan-Meier/HR results. The study is a PK similarity study, not an efficacy study with a time-to-event endpoint.待处理
Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.StrokePMID 37800372无 PMCID2023-Nov0.98未发现恶性肿瘤人群证据。待处理
DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation.Clin NutrPMID 37806075PMC105917242023-Nov0.98未发现恶性肿瘤人群证据。待处理
The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).Colorectal DisPMID 37837240无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Nat MedPMID 37840095PMC106670992023-Nov0.98未发现恶性肿瘤人群证据。待处理
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.Nat MedPMID 37845511PMC106670902023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Nat MedPMID 37845512PMC106670982023-Nov0.98未发现恶性肿瘤人群证据。待处理
Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.Br J CancerPMID 37864049PMC106672122023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.Lancet OncolPMID 37875143无 PMCID2023-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.Lancet HaematolPMID 37914482无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.J Natl Compr Canc NetwPMID 37935109PMC109767482023-Nov0.85This is a secondary analysis of a Phase III trial focusing on a predictive biomarker (vitamin D) for a toxicity endpoint (chemotherapy-induced peripheral neuropathy), not on a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the inclusion criteria.待处理
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.Cancer MedPMID 37935428PMC107097322023-Nov0.95The study is a Phase III randomized trial of a drug-containing intervention in oncology patients, but its primary efficacy endpoint is overall response rate (ORR), which is not a time-to-event endpoint. The record does not indicate any analysis of OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios for efficacy, so it does not meet the required primary/key secondary time-to-event efficacy endpoint criterion.待处理
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.Health Technol AssessPMID 37991196PMC110171532023-Nov0.95The record is a Phase III randomized trial in oncology with a time-to-event endpoint, but the intervention is radiation therapy alone without a drug component, which is an exclusion criterion.待处理
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety.TrialsPMID 37891616PMC106121552023-Oct-270.45This is a protocol for a Phase III randomized trial comparing two drugs for febrile neutropenia prevention in hematologic patients. While it meets criteria for oncology, human subjects, randomization, Phase III status, and drug intervention, it does not report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The abstract explicitly states it is a protocol (Clinical Trial Registration, Protocol Version) and does not present efficacy data. Therefore, it is excluded as it is not an original result report.待处理
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.N Engl J MedPMID 37888916PMC107574262023-Oct-260.98未发现恶性肿瘤人群证据。待处理
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.N Engl J MedPMID 37888917无 PMCID2023-Oct-260.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.Acta Derm VenereolPMID 37877618PMC106146512023-Oct-250.98未发现恶性肿瘤人群证据。待处理
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.LancetPMID 37633306无 PMCID2023-Oct-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.Eur Heart JPMID 37639462PMC105901312023-Oct-210.98未发现恶性肿瘤人群证据。待处理
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.LancetPMID 37865470无 PMCID2023-Oct-210.98未发现恶性肿瘤人群证据。待处理
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.J Clin OncolPMID 37364223PMC106024972023-Oct-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.J Clin OncolPMID 37643382PMC106025392023-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.J Clin OncolPMID 37651676PMC106025072023-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.VaccinePMID 37659893无 PMCID2023-Oct-200.98未发现恶性肿瘤人群证据。待处理
Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guérin (BCG) in the BATTLE trial.VaccinePMID 37743116无 PMCID2023-Oct-200.98未发现恶性肿瘤人群证据。待处理
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J MedPMID 37851874无 PMCID2023-Oct-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Reanalysis of a Randomized Controlled Trial.NeurologyPMID 37684058PMC105856792023-Oct-170.98未发现恶性肿瘤人群证据。待处理
SPOTlight on GLOW.Cell Rep MedPMID 37852180PMC105910462023-Oct-170.85The record describes a Phase 3 randomized trial in human oncology with a drug intervention. However, the provided abstract and metadata do not explicitly mention a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio. Therefore, the time-to-event criterion is not met.待处理
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.Arthritis Res TherPMID 37840134PMC105779822023-Oct-160.98未发现恶性肿瘤人群证据。待处理